Japan’s Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
May 01, 2023 at 01:34 AM EDT
The Japanese company said it would pay $40.00 per share of Iveric, which booked net loss of $185.2 million and had $534.7 million in net assets in 2022.
